October 23rd, 2020Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma William D. Tap, MD1,2; Victor M. Villalobos, MD, PhD3; Gregory M. Cote, MD, PhD4; Howard Burris, MD5; Filip Janku, MD,...
Read Article